Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Ask About Adherence: New study examines effects of synchronized prescription refill program on medication adherence

By Samantha Dougherty  |    August 31, 2016
Ask About Adherence is a blog series featuring Q&A’s with experts and new medication adherence resources. In this post, we feature a recently released study published in Health Affairs that explores...   Read More

Improving FDA’s combination product review process could increase epinephrine auto-injector competition

By Stephen J. Ubl  |    August 30, 2016
Combination products that consist of a medicine and delivery device are important treatment options for patients and have the potential to improve public health. Innovator companies invest in...   Read More

Medicare Monday: Who qualifies for Part D Extra Help?

By Nicole Longo  |    August 29, 2016
Over the past couple months, we’ve taken a look at three hypothetical Medicare beneficiaries who qualify for the Extra Help program, also known as the low-income subsidy. Learn more about the...   Read More

Empowering consumers and improving access to important clinical information

By Allyson Funk  |    August 29, 2016
Even though more Americans are insured than ever before, many are facing insurance barriers that may interfere with a doctor’s prescribed course of treatment and impact their care. We recently...   Read More

Fact Check Friday: The truth about biopharmaceutical patents

By Mark Grayson  |    August 26, 2016
MYTH: Biopharmaceutical companies use government-protected monopolies to raise costs on medicines. FACT: Patent-protected medicines routinely face competition from other brand name medicines, which...   Read More

Medicare Monday: Increased rebate levels in Part D show robust negotiation continues

By Nicole Longo  |    August 22, 2016
A key component of the success of Part D is the negotiation and competition that occurs, helping to keep costs low for beneficiaries and taxpayers. The way the program works is Part D purchasers...   Read More

New report highlights more than 250 vaccines in development

By Hannah Mooney Mack  |    August 18, 2016
More than 200 years ago, the first vaccine was developed for smallpox, and now, the disease has been eradicated worldwide. And in the United States, the transmission of poliovirus, measles and...   Read More

In biopharmaceutical research, if at first you don’t succeed, try again

By Andrew Powaleny  |    August 17, 2016
In case you missed it, an article in STAT News today profiles setbacks inside the process of researching new treatments and cures for patients. For America’s biopharmaceutical research companies,...   Read More

340B Spotlight: Retail pharmacies continue to expand the 340B program

By Rebecca Davison  |    August 17, 2016
One area of needed reform in the 340B program is the use of contract pharmacy arrangements. A new analysis by Drug Channels  found more than one-in-four retail, mail and specialty pharmacies in the...   Read More

Study finds actual cost of 14 new medicines is billions less than predicted

By Holly Campbell  |    August 16, 2016
In case you missed it, a forthcoming study will disprove – once again – misleading claims pharmacy benefit managers and insurers, among others, routinely make about spending on new innovative...   Read More

Medicare Monday: Concerns still abound about Part B proposal

By Allyson Funk  |    August 15, 2016
We’ve covered many of the concerns about the government’s overreaching proposal to change Medicare Part B payments and negatively impact seniors’ access to treatment. A lack of patient protections,...   Read More

Looking ahead to PDUFA VI

By Sascha Haverfield  |    August 11, 2016
Next Monday, PhRMA and BIO will participate alongside patient advocates and key stakeholders in the U.S. Food and Drug Administration’s (FDA) public meeting on the reauthorization of the Prescription...   Read More

340B Spotlight: New report raises questions about eligibility metric for 340B hospitals

By Karyn Schwartz  |    August 11, 2016
A new report from the Government Accountability Office (GAO) on how hospitals qualify for certain uncompensated care payments raises questions about how a similar eligibility metric is used to...   Read More

Dr. George Scangos: Not just science for science’s sake

By Andrew Powaleny  |    August 10, 2016
America’s biopharmaceutical researchers are working tirelessly to develop new and innovative medicines for patients. For those diseases that have no treatment options, the opportunity to improve...   Read More

Ask About Adherence: New article looks at addressing medication nonadherence in the United States

By Samantha Dougherty  |    August 9, 2016
Ask About Adherence is a blog series featuring Q&A’s with experts and new medication adherence resources. In this post, we feature a new article in the Journal of Patient Preference and Adherence,...   Read More

Medicare Monday: Majority of Part D prescriptions are generics

By Nicole Longo  |    August 8, 2016
In 2005, seniors used generic medicines only 54 percent of the time. Meanwhile, in 2015, the generic utilization rate was about 86 percent. What changed between 2005 and 2015? What program was...   Read More

Working together to combat global Zika threat

By Emma Van Hook  |    August 4, 2016
The Zika virus is top of mind as the 2016 Summer Olympic Games get underway tomorrow in Rio. While once thought to be confined to limited areas of Africa, Southeast Asia and the Pacific Islands, the...   Read More

Putting the cost of medicines in context

By Holly Campbell  |    August 4, 2016
Discussions about costs are important. No patient should have to worry about whether they can afford the care they need. At the same time, it is important to look at costs across the health care...   Read More

Guest Post: New bioethical Points to Consider on truthful and non-misleading product communication

By Guest Contributor  |    August 4, 2016
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Using setbacks as stepping stones in Alzheimer’s research

By Gretta Stone  |    August 3, 2016
For decades, biopharmaceutical researchers have worked tirelessly in the pursuit of new treatments and cures for the costly and devastating Alzheimer’s disease. Advancing treatments for Alzheimer’s...   Read More

What’s driving insurance premium increases? Hint: It’s not prescription drugs

By Allyson Funk  |    August 2, 2016
A new analysis from Avalere Health looks at 2017 proposed health insurance premium increases. As in 2016, insurers’ own data point to outpatient spending as the largest expected driver of premium...   Read More

Guest Post: New threats could fundamentally alter innovation in drug manufacturing

By Guest Contributor  |    August 2, 2016
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

ICYMI: NYT explores how immunotherapy is revolutionizing cancer care

By Holly Campbell  |    August 1, 2016
In case you missed it, this past weekend The New York Times published a series exploring the use of immunotherapy to combat cancer. Cell Wars features a primer on these new therapies and patient...   Read More

Medicare Monday: Part D premiums remain steady, 3 things to know

By Allyson Funk  |    August 1, 2016
Last week, the Centers for Medicare & Medicaid Services announced that average monthly premiums for Medicare Part D prescription drug coverage in 2017 will increase by just $1.50 per month to an...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates